JPWO2021067697A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067697A5 JPWO2021067697A5 JP2022520372A JP2022520372A JPWO2021067697A5 JP WO2021067697 A5 JPWO2021067697 A5 JP WO2021067697A5 JP 2022520372 A JP2022520372 A JP 2022520372A JP 2022520372 A JP2022520372 A JP 2022520372A JP WO2021067697 A5 JPWO2021067697 A5 JP WO2021067697A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- calcium channel
- type calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
他の実施形態
本発明をその詳細な説明と合わせて説明したが、前述の説明は、添付の特許請求の範囲によって定義される本発明の範囲を例証することを意図しており、限定することを意図していないことを理解されたい。他の態様、利点、および改変は、以下の特許請求の範囲内にある。
以下に、本願の当初の特許請求の範囲に記載の発明を列挙する。
［発明１］
神経毒性を有する哺乳動物を処置するための方法であって、Ｔ型カルシウムチャネル調節因子またはその塩を含む有効量の組成物を前記哺乳動物に投与して、前記哺乳動物における前記神経毒性の症状を低減することを含む方法。
［発明２］
前記哺乳動物が前記神経毒性を有すると特定することを含む、発明１に記載の方法。
［発明３］
前記哺乳動物がヒトである、発明１または２のいずれか１つに記載の方法。
［発明４］
神経毒性が化学療法剤誘発性神経毒性である、発明１から３のいずれか１つに記載の方法。
［発明５］
前記化学療法剤誘発性神経毒性がボルテゾミブ誘発性神経毒性である、発明４に記載の方法。
［発明６］
前記神経毒性を有する哺乳動物が、前記化学療法剤を投与されて、前記哺乳動物内のがんを処置したことがある、発明４または５のいずれか１つに記載の方法。
［発明７］
前記がんが、多発性骨髄腫、マントル細胞リンパ腫、白血病、消化管がん、肺がん、精巣がん、卵巣がん、脳腫瘍、子宮がん、前立腺がん、骨がん、乳がん、および膀胱がんからなる群から選択される、発明６に記載の方法。
［発明８］
前記症状が、疼痛、四肢脱力、四肢痺れ、痒み、知覚障害、麻痺、無嗅覚、下垂症、慢性咳嗽、運動機能障害、記憶喪失、視力低下、頭痛、認知障害、脳症、認知症、気分障害、便秘、性機能障害、膀胱性尿閉、および出血からなる群から選択される、発明１から７のいずれか１つに記載の方法。
［発明９］
前記Ｔ型カルシウムチャネル調節因子が負性調節因子である、発明１から８のいずれか１つに記載の方法。
［発明１０］
前記負性調節因子が負性アロステリック調節因子である、発明９に記載の方法。
［発明１１］
前記Ｔ型カルシウムチャネル調節因子がＴ型カルシウムチャネル活性を低減する、発明１から１０のいずれか１つに記載の方法。
［発明１２］
前記Ｔ型カルシウムチャネル調節因子がＣＸ－８９９８を含む、発明１から１１のいずれか１つに記載の方法。
［発明１３］
前記ＣＸ－８９９８が塩の形態である、発明１２に記載の方法。
［発明１４］
前記Ｔ型カルシウムチャネル調節因子がＣＸ－８９９８の代謝産物を含む、発明１から１１のいずれか１つに記載の方法。
［発明１５］
前記ＣＸ－８９９８の代謝産物が、
［発明１６］
前記ＣＸ－８９９８の代謝産物が塩の形態である、発明１５に記載の方法。
［発明１７］
前記Ｔ型カルシウムチャネル調節因子がＣＸ－８９９８および１種または複数のＣＸ－８９９８の代謝産物を含む、発明１から１１のいずれか１つに記載の方法。
［発明１８］
前記組成物が約１０ｎＭ～約１０００ｎＭの前記Ｔ型カルシウムチャネル調節因子を含む、発明１から１７のいずれか１つに記載の方法。
［発明１９］
前記組成物が、前記哺乳動物に対する前記Ｔ型カルシウムチャネル調節因子を、約３ｍｇ／ｋｇ前記哺乳動物の体重～約３０ｍｇ／ｋｇ前記哺乳動物の体重で含む、発明１から１８のいずれか１つに記載の方法。
［発明２０］
前記組成物が経口投与される、発明１から１９のいずれか１つに記載の方法。
Other Embodiments While the invention has been described in conjunction with a detailed description thereof, the foregoing description is intended to illustrate, and not limit, the scope of the invention as defined by the appended claims. Please understand that this is not intended. Other aspects, advantages, and modifications are within the scope of the following claims.
The inventions described in the original claims of this application are listed below.
[Invention 1]
A method for treating a mammal with neurotoxicity, the method comprising administering to said mammal an effective amount of a composition comprising a T-type calcium channel modulator or a salt thereof to treat symptoms of said neurotoxicity in said mammal. A method including reducing.
[Invention 2]
The method according to invention 1, comprising identifying the mammal as having the neurotoxicity.
[Invention 3]
The method according to any one of inventions 1 or 2, wherein the mammal is a human.
[Invention 4]
4. The method according to any one of inventions 1 to 3, wherein the neurotoxicity is chemotherapeutic agent-induced neurotoxicity.
[Invention 5]
5. The method according to invention 4, wherein the chemotherapeutic agent-induced neurotoxicity is bortezomib-induced neurotoxicity.
[Invention 6]
6. The method of any one of inventions 4 or 5, wherein said neurotoxic mammal has been administered said chemotherapeutic agent to treat cancer in said mammal.
[Invention 7]
The cancer is multiple myeloma, mantle cell lymphoma, leukemia, gastrointestinal cancer, lung cancer, testicular cancer, ovarian cancer, brain tumor, uterine cancer, prostate cancer, bone cancer, breast cancer, and bladder cancer. The method according to invention 6, wherein the method is selected from the group consisting of:
[Invention 8]
The symptoms include pain, limb weakness, limb numbness, itching, sensory impairment, paralysis, anosmia, ptosis, chronic cough, motor dysfunction, memory loss, visual impairment, headache, cognitive impairment, encephalopathy, dementia, and mood disorder. , constipation, sexual dysfunction, urinary bladder retention, and bleeding.
[Invention 9]
9. The method according to any one of inventions 1 to 8, wherein the T-type calcium channel regulator is a negative regulator.
[Invention 10]
The method according to invention 9, wherein the negative regulator is a negative allosteric regulator.
[Invention 11]
11. The method according to any one of inventions 1 to 10, wherein the T-type calcium channel modulator reduces T-type calcium channel activity.
[Invention 12]
12. The method according to any one of inventions 1 to 11, wherein the T-type calcium channel modulator comprises CX-8998.
[Invention 13]
The method according to invention 12, wherein the CX-8998 is in the form of a salt.
[Invention 14]
12. The method according to any one of inventions 1 to 11, wherein the T-type calcium channel modulator comprises a metabolite of CX-8998.
[Invention 15]
The metabolite of CX-8998 is
[Invention 16]
The method according to invention 15, wherein the metabolite of CX-8998 is in the form of a salt.
[Invention 17]
12. The method according to any one of inventions 1 to 11, wherein the T-type calcium channel modulator comprises CX-8998 and one or more metabolites of CX-8998.
[Invention 18]
18. The method of any one of inventions 1-17, wherein said composition comprises about 10 nM to about 1000 nM of said T-type calcium channel modulator.
[Invention 19]
Any one of inventions 1 to 18, wherein said composition comprises said T-type calcium channel modulator for said mammal at about 3 mg/kg body weight of said mammal to about 30 mg/kg body weight of said mammal. Method described.
[Invention 20]
20. The method according to any one of inventions 1 to 19, wherein said composition is administered orally.
Claims (20)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909694P | 2019-10-02 | 2019-10-02 | |
| US62/909,694 | 2019-10-02 | ||
| PCT/US2020/053944 WO2021067697A1 (en) | 2019-10-02 | 2020-10-02 | Methods and materials for treating neurotoxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550450A JP2022550450A (en) | 2022-12-01 |
| JPWO2021067697A5 true JPWO2021067697A5 (en) | 2023-10-11 |
Family
ID=75336496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520372A Pending JP2022550450A (en) | 2019-10-02 | 2020-10-02 | Methods and materials for treating neurotoxicity |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220354834A1 (en) |
| EP (1) | EP4041225A4 (en) |
| JP (1) | JP2022550450A (en) |
| KR (1) | KR20220075388A (en) |
| CN (1) | CN114760998A (en) |
| AU (1) | AU2020358075A1 (en) |
| BR (1) | BR112022006016A2 (en) |
| CA (1) | CA3153279A1 (en) |
| IL (1) | IL291823A (en) |
| MX (1) | MX2022004024A (en) |
| TW (1) | TW202122084A (en) |
| WO (1) | WO2021067697A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3364993T3 (en) | 2015-10-22 | 2023-01-09 | Cavion Inc | APPROACHES TO THE TREATMENT OF ANGELMAN SYNDROME |
| MX2019012818A (en) | 2017-04-26 | 2020-07-14 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders. |
| CN113164393A (en) | 2018-10-03 | 2021-07-23 | 卡维昂公司 | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide |
| CN117693342A (en) * | 2021-05-24 | 2024-03-12 | 卡维昂公司 | Method for treating essential tremor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677288A (en) * | 1991-05-15 | 1997-10-14 | Cypros Pharmaceutical Corporation | Use of aminoglycosides to protect against excitotoxic neuron damage |
| US7112319B2 (en) * | 2001-04-06 | 2006-09-26 | The Research Foundation Of The City University Of New York | Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| AU2007238755B2 (en) * | 2006-04-12 | 2012-07-12 | Merck Sharp & Dohme Llc | Pyridyl amide T-type calcium channel antagonists |
| WO2008112715A2 (en) * | 2007-03-12 | 2008-09-18 | Vm Discovery Inc. | Novel agents of calcium ion channel modulators |
| US10292989B2 (en) * | 2014-03-28 | 2019-05-21 | University Of Virginia Patent Foundation | General anesthetics that are not neurotoxic |
| WO2018217845A1 (en) * | 2017-05-26 | 2018-11-29 | Chase Therapeutics Corporation | Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies |
| CN113164393A (en) * | 2018-10-03 | 2021-07-23 | 卡维昂公司 | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide |
-
2020
- 2020-09-30 TW TW109134296A patent/TW202122084A/en unknown
- 2020-10-02 BR BR112022006016A patent/BR112022006016A2/en unknown
- 2020-10-02 EP EP20870765.3A patent/EP4041225A4/en active Pending
- 2020-10-02 JP JP2022520372A patent/JP2022550450A/en active Pending
- 2020-10-02 CN CN202080083640.7A patent/CN114760998A/en active Pending
- 2020-10-02 IL IL291823A patent/IL291823A/en unknown
- 2020-10-02 US US17/766,113 patent/US20220354834A1/en active Pending
- 2020-10-02 AU AU2020358075A patent/AU2020358075A1/en active Pending
- 2020-10-02 CA CA3153279A patent/CA3153279A1/en active Pending
- 2020-10-02 WO PCT/US2020/053944 patent/WO2021067697A1/en unknown
- 2020-10-02 MX MX2022004024A patent/MX2022004024A/en unknown
- 2020-10-02 KR KR1020227014666A patent/KR20220075388A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL270137B2 (en) | T-type calcium channel antagonist for use in treating dravet syndrome | |
| MX2007003795A (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases. | |
| BRPI0510094A (en) | use of flibanserin for premenstrual treatment and other female sexual disorders | |
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| WO2008037257A3 (en) | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors | |
| WO2010019702A3 (en) | Ddr1-binding agents and methods of use thereof | |
| Xu et al. | Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo | |
| JPWO2021067697A5 (en) | ||
| GB0202002D0 (en) | Use | |
| MA30777B1 (en) | USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER | |
| RU2010116859A (en) | APPLICATION OF 3,11b-CIS-DIHYDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND AUTOIMMUNE MYELITIS | |
| MX2022013650A (en) | Imidazopyrimidines as modulators of il-17. | |
| MX2021011488A (en) | Compounds and uses thereof. | |
| SG171674A1 (en) | Methods of treating cancer by administering human il-18 combinations | |
| ECSP088842A (en) | METHOD FOR INHIBITING THE KINK OF THE C? KIT | |
| Jung et al. | Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®) | |
| MX2023009294A (en) | Oxa-ibogaine inspired analogues for treatment of neurological and psychiatric disorders. | |
| Ravikumar et al. | Basal ganglionic angioleiomyoma | |
| MX2021008903A (en) | Compounds and uses thereof. | |
| MD2849F1 (en) | Method of mammary cancer treatment to patients of old age | |
| RU2008123889A (en) | APPLICATION OF A MICROSPHERIC CARBON ADSORBENT FOR TREATMENT OF AN IRRITATED FAT INTESTINE SYNDROME | |
| Hornung et al. | A case of virilization induced by a Krukenberg tumor from gastric cancer | |
| MX2022012632A (en) | Use of bromodomain inhibitors for treatment of huntington's disease. | |
| Villalon et al. | Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis | |
| GRASSO | RATIONAL DESIGN AND SYNTHESIS OF NOVEL POTENTIAL CB2 RECEPTOR ALLOSTERIC MODULATORS |